Instructional Video Highlights the Importance of AIMS Exam for Detecting and Monitoring Tardive Dyskinesia
In this instructional video, Dr. Rakesh Jain, co-chair of Psych Congress, emphasizes the importance of the Abnormal Involuntary Movement Scale (AIMS) in diagnosing and monitoring tardive dyskinesia (TD). Dr. Jain details the components, scoring, and procedure for conducting the AIMS exam.
Deutetrabenazine Proven Effective and Safe for Long-Term Tardive Dyskinesia Management
Tardive dyskinesia (TD), often associated with dopamine receptor antagonist (DRA) use, affects individuals with psychotic or mood disorders. This study evaluated the long-term efficacy and safety of deutetrabenazine, a VMAT2 inhibitor, in 343 patients through the RIM-TD open-label extension study.
Understanding the Differences Between Tardive Dyskinesia and Other Movement Disorders
Tardive dyskinesia (TD) is an involuntary movement disorder that develops as a side effect of long-term use of medications that block dopamine receptors, such as antipsychotics.
Early Diagnosis and Treatment Essential for Managing Tardive Dyskinesia and Minimizing Risks
Tardive dyskinesia (TD) is a movement disorder caused by long-term use of dopamine receptor-blocking agents, especially antipsychotics.
Experts Discuss Managing Co-Occurring Drug-Induced Parkinsonism and Tardive Dyskinesia
In a discussion led by Rakesh Jain, MD, MPH, experts Rajeev Kumar, MD, and Jonathan Meyer, MD, explored the complexities of treating patients with both drug-induced parkinsonism and tardive dyskinesia (TD). They emphasized the importance of reducing antipsychotic dosage when possible and using amantadine to manage parkinsonism without worsening TD. If dosage reduction isn’t feasible, switching to a weaker D2 blocker like clozapine was suggested.
Managing VMAT2 Inhibitor Side Effects for Tardive Dyskinesia
At the 2021 Psych Congress Regionals, Dr. Rakesh Jain discussed the symptoms of tardive dyskinesia and provided updates on treatments, focusing on VMAT2 inhibitors. He addressed common side effects of the FDA-approved VMAT2 inhibitors, valbenazine and deutetrabenazine, and offered strategies for managing these side effects.
Self-Care Strategies to Alleviate Tardive Dyskinesia Symptoms: Stress Reduction, Lifestyle Hacks, and Support
To minimize the symptoms of tardive dyskinesia (TD), stress reduction is key. Self-care gives those impacted by TD the mental and physical energy needed to cope with the many challenges of living with its symptoms.
Expert Panel Sets Guidelines for Assessing Tardive Dyskinesia Impact
Tardive dyskinesia (TD) is a movement disorder causing involuntary movements that severely impact patients’ physical, cognitive, and psychosocial functioning. Despite its significant effects, routine clinical practice often lacks measures to assess TD’s functional impact.
Coping with Tardive Dyskinesia: Strategies for Managing Symptoms and Enhancing Well-Being
Living with tardive dyskinesia (TD) presents challenges, from the distressing symptoms to the impact on daily life. Though symptoms like involuntary movements can be disruptive and self-consciousness-inducing, they might not be as noticeable to others as feared. Developing coping techniques and seeking support from mental health professionals can help navigate life with TD. Early detection and treatment are crucial, with medications like valbenazine and deutetrabenazine offering hope. Keeping a symptom diary can aid in monitoring progress and communicating effectively with healthcare providers. Prioritizing sleep and stress management can also alleviate symptoms, emphasizing self-care strategies to improve overall well-being.
Exploring the Genetic Factors in Tardive Dyskinesia Development and Management
The development of tardive dyskinesia (TD) is influenced by various factors including the type of antipsychotic, dose, duration of treatment, and individual genetic susceptibility. Studies have highlighted the role of genetic variations influencing the pharmacokinetics and pharmacodynamics of drugs, such as variations in dopamine, serotonin, and cannabinoid receptors, oxidative stress factors, and certain enzymes and transporters like CYP isoenzymes. Understanding these genetic factors is crucial as they contribute to the variability in drug metabolism and response, affecting both the efficacy and the adverse effects of antipsychotics.
